1. Update on diagnosis, pathogenesis and management of ketosis-prone type 2 diabetes mellitus;Smiley;Diabetes Manag (Lond),2011
2. Diabetic ketoacidosis and related events in the Canagliflozin Type 2 Diabetes Clinical Program;Erondu;Diabetes Care,2015
3. U.S. Food and Drug AdministrationFDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed July 13, 2017.
4. European Medicines AgencyEMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f. Accessed July 13, 2017.
5. Sodium-glucose cotransporter-2 inhibition and the insulin:glucagon ratio: unexplored dimensions;Kalra;Indian J Endocrinol Metab,2015